In a selected population of postmenopausal patients with HR+/HER2- breast cancer, NET is efficient to improve surgical outcome and better tolerated compared with chemotherapy.4 Phase 3 NET trials have demonstrated clinical response rates in approximately half of patients with anti-aromatases, and an improvement of up to 40% of BCS rates.9,10,16,17 Nevertheless, few data are available on both survival and prognostic factors in these patients. The gene discussed is CYP19A1; the disease is breast carcinoma.